Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data

Mizuho maintained its Outperform rating and $48 price target on Harmony Biosciences (HRMY), citing strong Q1 2025 financial results that surpassed expectations with $184.7 million in revenue and $1.03 EPS, driven by 20% year-over-year growth in Wakix sales. The firm highlighted positive preclinical data for HRMY's orexin 2 receptor agonist, BP1.15205, which demonstrated superior potency and could be a best-in-class asset despite being early-stage. This, coupled with a patent settlement extending Wakix's exclusivity to at least January 2030 and a robust financial position, underpins Mizuho's confidence in HRMY's pipeline, ahead of a key Phase 3 readout for ZYN-002 in Q3 2025.

Analysis

Harmony Biosciences (HRMY) presents a compelling investment case underpinned by strong analyst conviction, robust financial performance, and a de-risked commercial outlook. Mizuho's reaffirmation of its Outperform rating and $48.00 price target highlights significant potential upside from the current price, a view supported by the company's recent operational execution. Harmony reported a strong first quarter for 2025, with revenue of $184.7 million representing 20% year-over-year growth and an EPS of $1.03 that substantially beat the $0.61 forecast, driven by its primary asset, Wakix. Critically, the recent patent litigation settlement with Lupin extends Wakix's market exclusivity until at least January 2030, securing a vital cash flow stream to fund pipeline development. This pipeline contains two key potential value drivers: the near-term Phase 3 readout for ZYN-002 in Fragile X Syndrome expected in Q3 2025, and the longer-term, potentially best-in-class orexin 2 receptor agonist, BP1.15205. Despite being early-stage, preclinical data for BP1.15205 indicates superior potency compared to more advanced competitors. The company's financial stability is further evidenced by a strong cash position and an attractive P/E ratio of 12.76, suggesting the current valuation may not fully reflect these positive catalysts.

Key Decisions for Investors

• Given the combination of a 20% revenue growth rate, a low P/E ratio of 12.76, and a secured revenue runway for its key drug Wakix until 2030, investors could view the current stock price as an attractive entry point.
• Investors should closely monitor the upcoming Phase 3 data for ZYN-002 in Q3 2025, as this represents a significant binary event and a primary near-term catalyst for the stock's valuation.
• While the preclinical data for the orexin agonist BP1.15205 is promising for a long-term thesis, it is crucial to track its progression into human trials and acknowledge the inherent risks of its early development stage relative to competitors.